JPH0366608A - Remedy for tragomaschalia comprising adrenocortical steroid as main agent - Google Patents
Remedy for tragomaschalia comprising adrenocortical steroid as main agentInfo
- Publication number
- JPH0366608A JPH0366608A JP20040189A JP20040189A JPH0366608A JP H0366608 A JPH0366608 A JP H0366608A JP 20040189 A JP20040189 A JP 20040189A JP 20040189 A JP20040189 A JP 20040189A JP H0366608 A JPH0366608 A JP H0366608A
- Authority
- JP
- Japan
- Prior art keywords
- tragomaschalia
- steroid
- secretion
- armpit
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract description 9
- 239000003470 adrenal cortex hormone Substances 0.000 title abstract 4
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 12
- 239000003246 corticosteroid Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 9
- 230000007794 irritation Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002075 main ingredient Substances 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 12
- 150000003431 steroids Chemical class 0.000 abstract description 11
- 241000894006 Bacteria Species 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 1
- 229960004544 cortisone Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 description 12
- -1 steroid compounds Chemical class 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 241000186031 Corynebacteriaceae Species 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000040 apocrine gland Anatomy 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
末剤は副腎皮質ステロイドを用いたワキガ治療薬に関す
る。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The powder relates to a drug for treating armpit irritation using corticosteroids.
(従来の技術)
これまでワキガ症の対策あるいは治療法としては、消臭
剤による臭気の中和、制汗剤等による細菌繁殖環境の抑
制、抗生物質および殺菌剤等の抗細菌物質による細菌の
活動抑止と殺菌等々数多くの試みがなされてきた。(Prior art) Up until now, countermeasures or treatments for armpit rash have included neutralizing the odor using deodorants, suppressing the bacterial breeding environment using antiperspirants, and using antibacterial substances such as antibiotics and bactericidal agents. Numerous attempts have been made to suppress its activity and sterilize it.
ワキガ症に関連するアポクリン腺等の上皮ステロイ)’
分子l1mは、コレステロール、性ホルモン等のステロ
イド化合物を代謝・分泌しているが、分泌されるステロ
イドの種類は多様である。特に、離出分泌(分泌の際、
腺細胞の一部がくびれで分泌物、細胞質の一部を含んだ
まま、切れて出て行く型の分泌)を行っているアボクリ
ン腺からは、ステロイド代謝経路における中間生成物ま
で排出されるため、分泌されるステロイド化合物の種類
は極めて多様である。Epithelial steroids such as apocrine glands related to armpit syndrome)'
Molecule l1m metabolizes and secretes steroid compounds such as cholesterol and sex hormones, but the types of steroids secreted are diverse. In particular, secretion (during secretion,
Intermediate products in the steroid metabolic pathway are also excreted from avoccrine glands, where some of the glandular cells produce secretions at the constriction (a type of secretion in which the glandular cells cut off and exit while containing some of the cytoplasm). The types of steroid compounds secreted are extremely diverse.
ワキガ臭はこれらの中のある種のステロイド化合物が、
わきの下上皮で定着繁殖している細菌叢によって代謝さ
れて産生した臭気性ステロイド化合物、5 α−and
rost−16−en−3−on(5α−A)によるも
のである。Armpit odor is caused by certain steroid compounds among these.
5 α-and odorous steroid compounds, metabolized and produced by the bacterial flora that colonize and proliferate in the axillary epithelium.
rost-16-en-3-on (5α-A).
しかし、この化合物自体はわきの下分泌組織から分泌さ
れた分泌液からは検出されておらず、5αA−化合物は
分泌&[l獄内で代謝産出された、C,、ステロイド化
合物がわきの下に定着している細菌によって再代謝され
て産生しているとするのが−船釣学説である。However, this compound itself has not been detected in the fluid secreted from the axillary secretory tissue, and the 5αA-compound is secreted and metabolized in the body, and the steroid compound settles in the armpit. The Funatsuri theory holds that it is re-metabolized and produced by the bacteria in the body.
上皮に定着している細菌としては、好気性菌であるブド
ウ球菌、好気性コリネフォルムバクテリア、嫌気性菌で
あるプロピオニバクテリウム等が挙げられるが、このう
ちコリネフォルムバクテリアグループ、プロピオニバク
テリウムの多くとブドウ球菌の一部にステロイド代謝機
能を有する菌種が存在する。Bacteria that colonize the epithelium include aerobic bacteria Staphylococcus, aerobic Coryneform bacteria, and anaerobic bacteria Propionibacterium, among which Coryneform bacteria group, Propionibacterium There are many species of Staphylococcus and some Staphylococci that have steroid metabolism functions.
(発明の解決すべき課題)
ワキガ臭発生の機序は上述の通りであり、したがってワ
キガ症対策としては主として抗生物質その他の抗細菌物
質をわきの下へ塗布し、わきの下上皮に定着している細
菌を除去することによって臭気性ステロイドの産生を抑
えることによって行われている。(Problem to be Solved by the Invention) The mechanism of armpit odor is as described above, and therefore, the main method of preventing armpit odor is to apply antibiotics and other antibacterial substances to the armpits to kill the bacteria colonized in the armpit epithelium. This is done by suppressing the production of odorous steroids by removing them.
しかし、それらの効果は抗細菌作用の消失によって細菌
が再定着するまでの一時的なものにすぎず、ワキガ症の
根絶治療は外科的処置にのみ頼っているのが現状である
。However, these effects are only temporary until the antibacterial effect disappears and the bacteria recolonize, and current eradication treatment for armpit irritation relies solely on surgical treatment.
本発明者等は、生態組織のステロイド化合物合成・分泌
抑制作用を主作用とするワキガの治療法の開発に努め、
外科的な処置によらずにワキガを迅速に根絶させること
のできる治療薬の発見を課題として研究に力を注いでき
た。The present inventors have endeavored to develop a treatment method for armpit moth whose main effect is to suppress the synthesis and secretion of steroid compounds in biological tissues.
He has focused his efforts on research to find a drug that can quickly eradicate armpit moths without surgical treatment.
(課題を解決するための手段)
前記従来技術の課題は主剤としての副腎皮質ステロイド
および補助剤としての抗細菌物質を夫々有効量で含むこ
とを特徴とするワキガ治療薬によって解決される。(Means for Solving the Problems) The problems of the prior art described above are solved by a drug for treating armpit irritation, which is characterized by containing effective amounts of a corticosteroid as a main ingredient and an antibacterial substance as an adjuvant.
(作用)
本発明のワキガ治療薬においては、主剤としての副腎皮
質ステロイド剤と補助剤としての抗細菌物質との相乗作
用により従来外用薬によっては根絶が困難とされていた
ワキガ症が極めて短時日の治療によって完治に到る。(Action) The drug for treating armpit irritation of the present invention eliminates armpit irritation in an extremely short period of time due to the synergistic action of the corticosteroid as the main agent and the antibacterial substance as an adjuvant. Complete recovery can be achieved through treatment.
こ\で、本発明のワキガ治療薬における補助剤としての
抗細菌物質は従来においても用いられていたものであり
、したがって前記のような本発明の驚くべき作用は主と
して主剤としての副腎皮質ステロイドの効果によるもの
と考えられる。Therefore, the antibacterial substance used as an auxiliary agent in the drug for treating armpit irritation of the present invention has been used in the past, and therefore, the above-mentioned surprising effects of the present invention are mainly due to the use of corticosteroids as the main agent. This is thought to be due to the effect.
副腎皮質ステロイドは従来ワキガ治療には全く用いられ
たことがなく、したがってそのワキガ臭に対する具体的
な薬理作用も必ずしも明らかではないが、副腎皮質ステ
ロイドの持つ生理作用のひとつである生体組織のステロ
イド台底・分泌抑制作用によって、わきの下上皮分泌組
織からの臭気性ステロイド原因物質の分泌が抑制される
ことによるものと考えられる。Corticosteroids have never been used for the treatment of armpit odor, and therefore their specific pharmacological effects on armpit odor are not necessarily clear, but one of the physiological effects of corticosteroids is the steroid absorption in living tissue. This is thought to be due to the secretion of odorous steroids from the axillary epithelial secretory tissue being inhibited by the secretion suppressing effect.
たとえば、前記5α−Aワキガ臭化合物の細菌による産
生にはΔ”−CI9ステロイドの存在が不可欠であるこ
とから、副腎皮質ステロイドを局所的に高濃度で作用さ
せることによって、非可逆的かつ長期的にアボクリン腺
からのか−るステロイドの分泌が抑制されることによる
ものと推定される。For example, since the presence of Δ''-CI9 steroids is essential for bacterial production of the 5α-A armpit odor compound, it is possible to prevent irreversible and long-term effects by locally applying corticosteroids at high concentrations. This is presumed to be due to the suppression of steroid secretion from the avocrine glands.
従来、副腎皮質ステロイドをたとえば皮膚の炎症に対し
て外用するときの抗炎症作用は、炎症のケミカルメヂエ
ータとして重要なプロスタグランジンやロイコトリエン
の産生を減少させることによるものとされている。した
がって、アポクリン腺分泌物からの微住物代謝による前
記ワキガ臭化合物の副腎皮質ステロイドによる産生の抑
止は前記のような抗炎症作用の機序とは異なり、かつこ
れらからは容易に予測し得ないものである。Conventionally, the anti-inflammatory effect of corticosteroids when used externally to treat skin inflammation, for example, is thought to be due to the reduction in the production of prostaglandins and leukotrienes, which are important chemical mediators of inflammation. Therefore, the inhibition of the production of armpit odor compounds by corticosteroids through the metabolism of microorganisms from apocrine gland secretions is different from the mechanism of anti-inflammatory action described above, and cannot be easily predicted from these mechanisms. It is something.
本発明において主剤として用いる副腎皮質ステロイドと
しては、たとえばコーチシン、コーチゾール、ハイドロ
コーチシン、プレドニゾン、プレドニゾロン、メチルプ
レドニゾン、メチルプレドニゾロン、トリアムシノロン
、デキサメサゾン、バラメサゾン、ベータメサゾンおよ
びベータメサゾン等一般に知られているものから選択す
ることができる。The corticosteroid used as the main agent in the present invention is selected from commonly known ones such as cortiscin, cortisol, hydrocortiscin, prednisone, prednisolone, methylprednisone, methylprednisolone, triamcinolone, dexamethasone, valamethasone, betamethasone, and betamethasone. can do.
ワキガ症に対して副腎皮質ステロイドを塗布する際には
、わきの下上皮の細菌による副腎皮質ステロイド剤の取
り込み、作用阻害化合物の産生等によってその生理作用
が阻害される恐れがあるが、これらを考慮して副腎皮質
ステロイド剤を大量に塗布すると、その副作用として感
染症を誘発するおそれもある。When applying corticosteroids to treat armpit irritation, the physiological effects of corticosteroids may be inhibited due to uptake of the corticosteroid by bacteria in the armpit epithelium and the production of compounds that inhibit its action. If large amounts of corticosteroids are applied, there is a risk of inducing infection as a side effect.
このため本発明の治療剤においては、補助剤として1種
類、もしくは2種以上の抗細菌物質を含有させて、わき
の下上皮に定着している細菌を除去しないしはその活動
を抑止するようになされている。したがって前記補助剤
は従来のワキガ臭治療剤における殺菌、制菌それ自体の
機能よりはむしろ主剤としての副腎皮質ステロイドの効
果を最小限の投与量で有効に得るために用いられている
。For this reason, the therapeutic agent of the present invention contains one or more antibacterial substances as an adjuvant to prevent bacteria colonized in the axillary epithelium from being removed or to suppress their activity. ing. Therefore, the adjuvant is used to effectively obtain the effect of the corticosteroid as the main agent at a minimum dose, rather than the bactericidal or antibacterial function itself in conventional arm odor treatment agents.
主剤と組合せて用いられて抗細菌物質としては前記上皮
ステロイドの分泌物を代謝する細菌に対して有効な公知
の抗生物質および化学殺菌剤の中から適当に選択するこ
とができる。The antibacterial substance used in combination with the base agent can be appropriately selected from known antibiotics and chemical disinfectants effective against bacteria that metabolize the secretions of the epithelial steroids.
副腎皮質ステロイドによるワキガ症の治療効果は極めて
顕著かつ迅速であり、後記実施例に示すに床実験によれ
ば、約2mg以下の有効成分の−ないし二回の投与によ
って完全な治癒に到る場合がほとんどである。The therapeutic effect of corticosteroids on armpit rash is extremely pronounced and rapid, and according to bed experiments shown in the Examples below, complete cure can be achieved with one or two administrations of approximately 2 mg or less of the active ingredient. Most of them are.
なお、現在迄の実験治療の結果では治療後約6ケ月〜1
年8ケ月にわたって再発したケースはほとんどなく、長
期にわたる連用の必要がなかったため投与の副作用は全
く認められていない。Furthermore, according to the results of experimental treatments to date, the treatment period is about 6 months to 1 month after treatment.
There have been almost no cases of recurrence over the 8 months a year, and there has been no need for long-term continuous use, so no side effects have been observed.
実施例
以下本発明を実際のワキガ症患者に対する臨床試験結果
によって説明する。被験患者は昭和67年1り月〜平成
元年6月の期間において約170人であった。EXAMPLES The present invention will be explained below with reference to the results of clinical trials on actual patients with armpit syndrome. Approximately 170 patients were tested during the period from January 1987 to June 1989.
このような患者に対し、1g中に副腎皮質ステロイドと
してプレドニゾロン2mg、抗生物質として硫酸ワラジ
オマイシン3Bを含む軟膏形態の治療薬剤を一日一回通
常の方法でわき下に塗布した。For such patients, a therapeutic drug in the form of an ointment containing 2 mg of prednisolone as a corticosteroid and valadiomycin 3B as an antibiotic per gram was applied to the armpits once a day in the usual manner.
170人中はとんどの患者には一回の塗布で顕著な効果
(無臭化)が示され、その他の患者についても二回まで
の塗布で完全な治療効果が認められた。Most of the 170 patients showed a remarkable effect (odor-free) after one application, and complete therapeutic effects were observed for the other patients after up to two applications.
前記期間の経過後、追跡調査が不可能であった若干の患
者を除いては全くワキガが発生していないことが確認さ
れた。After the lapse of the above period, it was confirmed that no armpit irritation occurred at all, except for some patients who were unable to be followed up.
尚最近、治癒後にワキガ臭が再発した二側が報告され、
これらはいずれも治療後にワキの下に脱毛処理を施した
患者であった。Recently, there have been reports of two cases where armpit odor recurred after healing.
These were all patients who underwent hair removal treatment on their armpits after treatment.
その後、前記主成分としての副腎皮質ステロイドをメチ
ルプレドニゾロンおよびコーチシンとした薬剤によるそ
の後の試験でもはX′同様な治療効果が得られている。Subsequent tests using drugs containing methylprednisolone and cortiscin as the main ingredients of adrenal corticosteroids yielded therapeutic effects similar to X'.
(発明の効果)
本発明によれば、従来根治が困難とされていたワキガ症
に対して極く短時日の投薬で著しい治療効果が認められ
た。(Effects of the Invention) According to the present invention, a remarkable therapeutic effect was observed for armpit rash, which was conventionally thought to be difficult to cure, by administering medication for a very short period of time.
Claims (1)
の抗細菌物質を夫々有効量で含むことを特徴とするワキ
ガ治療薬。A drug for treating armpit irritation, characterized by containing an adrenal corticosteroid as a main ingredient and an antibacterial substance as an adjuvant in effective amounts.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20040189A JP2964152B2 (en) | 1989-08-03 | 1989-08-03 | Waqiga remedies mainly containing corticosteroids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20040189A JP2964152B2 (en) | 1989-08-03 | 1989-08-03 | Waqiga remedies mainly containing corticosteroids |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0366608A true JPH0366608A (en) | 1991-03-22 |
JP2964152B2 JP2964152B2 (en) | 1999-10-18 |
Family
ID=16423706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP20040189A Expired - Fee Related JP2964152B2 (en) | 1989-08-03 | 1989-08-03 | Waqiga remedies mainly containing corticosteroids |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2964152B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025624A1 (en) * | 1996-12-10 | 1998-06-18 | Nishiyama, Kenichi | Remedy for axillary osmidrosis containing adrenocorticosteriodal preparation |
-
1989
- 1989-08-03 JP JP20040189A patent/JP2964152B2/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025624A1 (en) * | 1996-12-10 | 1998-06-18 | Nishiyama, Kenichi | Remedy for axillary osmidrosis containing adrenocorticosteriodal preparation |
GB2334445A (en) * | 1996-12-10 | 1999-08-25 | Keiko Yamamoto | Remedy for axillary osmidrosis containing adrenocorticosteriodal preparation |
GB2334445B (en) * | 1996-12-10 | 2000-08-30 | Keiko Yamamoto | Remedy for axillary osmidrosis containing adrenocorticosteriodal preparation |
AU728134B2 (en) * | 1996-12-10 | 2001-01-04 | Nishiyama, Kenichi | Remedy for tragomaschalia containing adrenocorticosteriodal preparation |
US6180101B1 (en) | 1996-12-10 | 2001-01-30 | Keiko Yamamoto | Remedy for axillary osmidrosis containing adrenocorticosteroidal preparation |
KR100341172B1 (en) * | 1996-12-10 | 2002-06-20 | 니시야마 겐이치 | Remedy for axillary osmidrosis containing adrenocorticosteriodal preparation |
Also Published As
Publication number | Publication date |
---|---|
JP2964152B2 (en) | 1999-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3856934A (en) | Skin depigmentation | |
RU2470645C2 (en) | Pharmaceutical composition for local application containing combination of fusidic acid and corticosteroid | |
JPH10509437A (en) | Deodorant, antimicrobial and preservative compositions and methods of using them | |
US4012508A (en) | Topical composition and method | |
JPH02501739A (en) | steroid lotion | |
US6495531B2 (en) | Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain | |
JP5578880B2 (en) | Anti-malassezia agent | |
KR101642537B1 (en) | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it | |
JP2011173837A5 (en) | ||
JP2014516962A (en) | Compositions and methods for the treatment of skin diseases | |
Pochi | Acne: Androgens and microbiology | |
JP2000095683A (en) | Skin lotion | |
JPH0366608A (en) | Remedy for tragomaschalia comprising adrenocortical steroid as main agent | |
JP2617139B2 (en) | Combination of tobramycin and steroids for topical ophthalmic use | |
US4466956A (en) | Method of therapy for oral herpes simplex | |
DE2806866B2 (en) | Use of salts of dithiodialkane sulfonic acids | |
AU728134B2 (en) | Remedy for tragomaschalia containing adrenocorticosteriodal preparation | |
CN101375837B (en) | Medicament composition for treating dermatopathy as well as preparation method and use thereof | |
CN1989950A (en) | Sterilizing effective antipruritic application agent | |
JP2008520694A (en) | Compositions and methods for promoting healing of non-healing and delayed healing wounds and ulcers | |
JPS6051114A (en) | Remedy and preventive for contact dermatitis | |
RU2124355C1 (en) | Method of an agent devising for wound treatment | |
JPH10236955A (en) | Therapeutic agent for common acne containing adrenocortical steroid as active ingredient | |
KR20220129790A (en) | Composition Comprising Harpagoside for Wound Healing | |
JP2001187741A (en) | Skin care medicinal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080813 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |